SignalPath, a Raleigh, NC-based clinical trial technology startup, closed a $18M Series B funding round.
The round brought total funding raised to date to $35M.
The company intends to use the funds to grow the research teams and products.
Led by Dr. Brad Hirsch, Co-Founder & CEO, SignalPath is a clinical trial technology partner for research sites and sponsors, focused on improving efficiency of trial execution and management.
The company’s suite of tools covers the needs of all stakeholders in the site ecosystem including coordinator, finance, regulatory and management teams. The product has expanded beyond its original focus as a Clinical Trial Management System (CTMS) to address key pain points from study design to trial startup to study oversight for site management organizations.
It currently supports over 2,500 trials across 250 sites and 3,000 active users.
FinSMEs
22/10/2019